PeerVoice Oncology & Haematology Audio
By PeerVoice
Listen to a podcast, please open Podcast Republic app. Available on Google Play Store and Apple App Store.
Image by PeerVoice
Category: Science
Open in Apple Podcasts
Open RSS feed
Open Website
Rate for this podcast
Subscribers: 21
Reviews: 0
Episodes: 152
Description
PeerVoice is committed to producing and distributing evidence-based, independently-created medical education in Oncology & Haematology that is designed to positively impact patient care. Activities can either be accredited or non-accredited but are always driven by the learning and practice needs of healthcare professionals. Learn more at: https://peervoice.com.
| Episode | Date |
|---|---|
|
Andrea Necchi, MD - Working With Our Patients as a Member of the MDT: A Bladder Cancer Awareness Month 2026 CME Initiative
|
Jun 09, 2026 |
|
Javier Cortés, MD, PhD / Laura Huppert, MD - Novel Uses for Trusted Tools: Investigational Approaches for TROP2-Directed ADCs in Advanced Breast Cancer
|
Jun 05, 2026 |
|
Silvia Stacchiotti, MD / Michiel van de Sande, MD, PhD - Surgical Interventions and Systemic Innovations: Collaborative Approaches to Tenosynovial Giant Cell Tumour as Pharmacological Advances Emerge
|
Jun 05, 2026 |
|
Trisha Wise-Draper, MD, PhD - Beyond the Virus: New Strategies to Improve Outcomes of Non-HPV-Associated Recurrent/Metastatic Head and Neck Cancer
|
May 26, 2026 |
|
Marwan Fakih, MD - Making a Difference in Refractory Metastatic Colorectal Cancer: Practical Strategies to Positively Impact the Patient Journey Across Practice Settings
|
May 26, 2026 |
|
Martin Köbel, MD - Scoring Folate Receptor-Alpha Expression in Gynecological Cancers: An Interactive Pathology Masterclass
|
May 18, 2026 |
|
Austin Kulasekararaj, MD, MRCP, FRCPath - From Life-Threatening to Life-Optimised: The Evolving Management of Paroxysmal Nocturnal Haemoglobinuria Across the Complement Cascade
|
Mar 25, 2026 |
|
Pier Luigi Zinzani, MD, PhD - Recognising and Responding to a Rare Disease: A Case-Based Exploration of the Ideal iMCD Patient Journey
|
Mar 25, 2026 |
|
Jonathan W. Goldman, MD / Misty Dawn Shields, MD, PhD - The Emerging Nuances of Extensive-Stage SCLC Treatment: Individualizing Care in the Immunotherapy Era
|
Mar 06, 2026 |
|
Cristina Saura Manich, MD, PhD - First-Line Treatment of HER2-Positive Metastatic Breast Cancer: Could Investigational Approaches Improve on Current Standard of Care?
|
Feb 25, 2026 |
|
Matthew J. Koster, MD - VEXAS Syndrome Asked and Answered: Everything You Want To Know And More
|
Feb 25, 2026 |
|
Rebecca Dent, MD, FRCP (Canada) - TROP2 and Triple-Negative Breast Cancer: The Rationale and Emerging Evidence for Exploring the Therapeutic Potential of TROP2-Targeted Antibody-Drug Conjugates in Earlier Lines and Disease-Stage Settings
|
Jan 07, 2026 |
|
Steven Horwitz, MD - Relapsed/Refractory Peripheral T-Cell Lymphoma: Reviewing Available and Anticipated Strategies in This Rare Malignancy
|
Dec 17, 2025 |
|
Francesco Passamonti, MD - Myelofibrosis Under the Microscope: Exploring p53 Dysregulation as a Potential Therapeutic Target
|
Dec 17, 2025 |
|
Sanjay Popat, FRCP, PhD - Don’t Forget About HER2: Clinical Insights and Novel Therapies for HER2-Mutant NSCLC From ESMO 2025
|
Nov 08, 2025 |
|
Fred Saad, MD, FRCS - From Platform to Practice: Insights From ESMO 2025 on the Latest Data Guiding Contemporary Care in mHSPC and nmCRPC
|
Oct 30, 2025 |
|
Nadia Harbeck, MD, PhD - Antibody-Drug Conjugates in Breast Cancer: Keeping Abreast of the Latest Data As They Emerge From ESMO
|
Oct 30, 2025 |
|
Naveen Pemmaraju, MD - How I Treat BPDCN: A Case-Based Exploration of Best Practices in Selecting and Providing Therapeutic Strategies
|
Oct 08, 2025 |
|
Solange Peters, MD, PhD - Pioneering Precision: A Real-World Roadmap to Optimal Outcomes in NTRK Fusion-Positive and HER2-Mutant Advanced NSCLC
|
Oct 03, 2025 |
|
Alicia K. Morgans, MD, MPH - Clinical Conversations in Castration-Resistant Prostate Cancer: Best Practices in Discussing Testing and Treatment With Patients
|
Oct 01, 2025 |
|
Neal Shore, MD, FACS - Redefining Expectations in mHSPC: Options and Opportunities Across the Spectrum of Disease
|
Aug 20, 2025 |
|
Lorenza Rimassa, MD - Shifting the Paradigm in Biliary Tract Cancers: Contemporary Data and Decision-Making
|
Aug 19, 2025 |
|
Enriqueta Felip, MD, PhD - Targeting TROP2 in Advanced NSCLC: What Do We Know From Recent Clinical Trials?
|
Aug 19, 2025 |
|
Alison Birtle, FRCP, FRCR, MD - Case Study Challenge in Advanced Bladder Cancer: Tailoring Treatment to Individual Patients
|
Jul 21, 2025 |
|
Solange Peters, MD, PhD - Partnering With Patients: Shared Decision-Making in Locally Advanced, Unresectable EGFR-Mutated Non-Small Cell Lung Cancer
|
Jul 21, 2025 |
|
Adam Brufsky, MD, PhD / Rebecca Dent, MD, FRCP (Canada) - Same Class, Different Agents: Practical Considerations for Managing Toxicities of Interest in Patients on TROP2-Directed Therapies in Breast Cancer
|
Jul 07, 2025 |
|
Chloe E. Atreya, MD, PhD / Marwan Fakih, MD - Focusing on the Patient in Front of Us: Expert Perspectives on Providing Patient-Centered Care for Refractory Metastatic Colorectal Cancer
|
May 16, 2025 |
|
Robert J. Motzer, MD - Advanced Renal Cell Carcinoma: Clinical Advances in Approaches to Combination Therapy
|
May 08, 2025 |
|
Dustin A. Deming, MD - Personalizing Treatment Pathways for Refractory Metastatic Colorectal Cancer: Informed Decision-Making When Disease Has Progressed
|
Apr 21, 2025 |
|
Diana N. Ionescu, MD - To Target We Need to Test: Why and How to Identify Folate Receptor Alpha-Positive Ovarian Cancer
|
Apr 21, 2025 |
|
Enrico Lopriore, MD, PhD - Are You Managing Pregnant Individuals? Then You Need to Know About Fetal-Neonatal Alloimmune Thrombocytopenia (FNAIT)
|
Mar 26, 2025 |
|
Alessandro M. Vannucchi, MD, PhD - Not All JAKis Are Equal: What Can Trials and Real-World Evidence Tell Us About Optimal Treatment Approaches in Myelofibrosis?
|
Mar 26, 2025 |
|
Amrita Krishnan, MD - The Specifics of Bispecific Antibodies for Multiple Myeloma
|
Mar 19, 2025 |
|
Claire Harrison, DM, FRCP, FRCPath - Patient-Centred Care in Cytopenic Myelofibrosis: Collaborative Conversations on Treatment Goals and Decisions
|
Mar 05, 2025 |
|
Albrecht Stenzinger, MD - Optimising the Molecular Profiling Journey for Patients With CCA: Applying Best Practices and Avoiding Pitfalls
|
Jan 13, 2025 |
|
Dirk Arnold, MD, PhD - Still in the Game! Optimising Treatment Sequencing in the Management of Relapsed or Refractory mCRC
|
Dec 27, 2024 |
|
Michael K. Wong, MD, PhD, FRCPC - When Anti-PD1 Therapy Fails: Could Oncolytic Immunotherapy Impact Outcomes in Advanced Melanoma?
|
Dec 13, 2024 |
|
Erika Hamilton, MD - Safety First: Recognising and Responding to Toxicities Associated With TROP2-Directed Therapies in Metastatic Breast Cancer
|
Dec 12, 2024 |
|
John Mascarenhas, MD - Working With Our Patients as Partners in Care: Addressing Disease- and Treatment-Related Burdens Associated With Cytopenic Myelofibrosis
|
Nov 21, 2024 |
|
Harry Paul Erba, MD, PhD - New Tools, New Considerations: Optimizing Our Approaches to Managing Newly Diagnosed FLT3-Mutant AML
|
Nov 15, 2024 |
|
Maurie Markman, MD - Testing Impacts Treatment: Applying Best Practices in HER2 Assessment in Solid Tumours
|
Nov 15, 2024 |
|
Neal Shore, MD, FAC - Advancing Care for mCRPC With Life-Prolonging Therapies: Existing and Emerging Roles for Radiopharmaceuticals
|
Nov 08, 2024 |
|
Richard Kim, MD - The Modern Art of Sequencing Later Lines of Treatment for Advanced Colorectal Cancer: Exploring Case Scenarios With the Experts
|
Nov 08, 2024 |
|
Ffion Davies, MBChB, FRCPCH, FRCEM - Managing Major Bleeding in Patients Receiving DOACs: Data, Developments, and Decision-Making in the ED
|
Nov 08, 2024 |
|
Ana Oaknin, MD, PhD - HER2 as an Actionable Target in Gynaecological Cancers: Implications of Therapeutic Advances on Clinical Practice
|
Nov 08, 2024 |
|
Karin Jordan, MD, PhD - Applying Foresight to Optimise Emesis Control in Patients Receiving Antibody-Drug Conjugates
|
Oct 25, 2024 |
|
Elena Castro, MD, PhD - Innovation and Individualisation in mHSPC and nmCRPC: Optimising Patient Outcomes and Experiences
|
Oct 25, 2024 |
|
Karin Jordan, MD, PhD - Practical Protocols for Preventing and Managing Antibody-Drug Conjugate-Associated Nausea and Vomiting
|
Oct 11, 2024 |
|
Peter Schmid, FRCP, MD, PhD - Staying at the Forefront of HER2 and TROP2-Directed Antibody-Drug Conjugate Advances in Breast Cancer
|
Oct 11, 2024 |
|
Simron Singh, MD, MPH - Addressing the Challenges of Treating Highly Proliferative Neuroendocrine Tumours: Review of the Latest Evidence
|
Sep 30, 2024 |
|
Andrea Necchi, MD - Practical Considerations for ADC-ICI Combinations in Advanced Urothelial Carcinoma: Identifying and Managing Adverse Events
|
Sep 30, 2024 |
|
Diana N. Ionescu, MD - Pathological Assessment of HER2 Status in Gastric and Gastroesophageal Cancers: Important Steps That Can Impact Outcomes
|
Sep 30, 2024 |
|
Elizabeth Smyth, MD, FRCP - When They Need More Than Trastuzumab: Deciding on What’s Next for Patients With HER2+ Gastric Cancer
|
Sep 23, 2024 |
|
Jacqueline S. Garcia, MD - Small Words, Big Differences: Best Practices in Supportive Care for Patients With AML
|
Aug 22, 2024 |
|
Brandon Blue, MD - Challenging Racial Disparities in Multiple Myeloma Treatment and Outcomes: Local Solutions to Address an Endemic Problem
|
Aug 22, 2024 |
|
Richard Kim, MD - From Trial Protocol to Routine Practice: Evaluating Real-World Evidence for Later-Line Treatments in Advanced Colorectal Cancer
|
Aug 22, 2024 |
|
Raffaele Califano, MD - At the Frontline in ALK+ NSCLC: Practical Approaches to TKI Therapy
|
Aug 02, 2024 |
|
Philippe Moreau, MD - Assessing Current and Potential Approaches in Multiple Myeloma: Updates From Madrid 2024
|
Aug 02, 2024 |
|
Gilles Salles, MD, PhD - Differentiating Decisions in Transplant-Ineligible Relapsed/Refractory DLBCL: What Are Our Options, and How Do We Choose Between Them?
|
Aug 02, 2024 |
|
Andrea Necchi, MD - Familiar Tools, New Uses? Assessing Novel Combination Approaches in the First-Line Management of Advanced Urothelial Carcinoma
|
Jul 22, 2024 |
|
Shaji Kumar, MD - Age Is More Than Just a Number: Tailoring Treatment Across the Multiple Myeloma Journey for Our Older and/or Unfit Patients
|
Jul 22, 2024 |
|
María-Victoria Mateos, MD, PhD - Updates in Multiple Myeloma From Madrid: Data Surrounding BCMA-Directed Agents and Their Clinical Relevance
|
Jul 22, 2024 |
|
David Malka, MD, PhD - Providing Cutting-Edge Care for Cholangiocarcinoma: Transforming the Patient Journey
|
Jul 22, 2024 |
|
Jonathan W. Riess, MD, MS - The Central Role of the Pathologist in Detecting MET Alterations: Enabling Multidisciplinary Teams to Do More With Less in NSCLC
|
Jun 03, 2024 |
|
Lindsey Roeker, MD - Differentiating Between BTK Inhibitors in CLL: Same Class, Distinctly Dissimilar Agents
|
May 21, 2024 |
|
Thomas Powles, MBBS, MRCP, MD - Optimising Outcomes for Our Patients With Advanced Urothelial Carcinoma: Best Practices and Future Directions in Maintenance Therapy
|
May 10, 2024 |
|
Sara Hurvitz, MD - A New Jigsaw Piece for Our Patient’s Puzzle: TROP2-Directed Therapy in HR+ Advanced Breast Cancer
|
May 10, 2024 |
|
Jeffrey Szer, MBBS, FRACP - The Quest for Optimal Haemolytic Control of Paroxysmal Nocturnal Haemoglobinuria
|
Apr 17, 2024 |
|
Dirk Arnold, MD - Navigating Decisions With Limited Tools: A Review of Best Practices in Managing Metastatic Colorectal Cancer
|
Apr 10, 2024 |
|
Lisa Licitra, MD - Are You Forearmed When Managing Toxicities Associated With Chemoradiotherapy in Patients With SCCHN?
|
Mar 28, 2024 |
|
Jonathan W. Goldman, MD - Don’t Forget About MET: Keys to Detecting and Targeting MET Alterations as a Therapeutic Vulnerability in NSCLC
|
Mar 26, 2024 |
|
Bertrand Tombal, MD, PhD - MDT Management of Patients Receiving Radioligand Therapy: Strategies to Optimise Outcomes
|
Mar 11, 2024 |
|
George Kassianos, CBE, MD (Hons), FRCGP / Gili Regev-Yochay, MD - Current 2024 COVID-19 Vaccination Campaign: The Evidence Supporting the Call to Action
|
Feb 28, 2024 |
|
Marwan Fakih, MD - The Science and the Art of Sequencing Therapies in Advanced CRC Beyond the Second Line
|
Feb 27, 2024 |
|
Amy E. DeZern, MD, MHS - Small Words Make Large Differences: Best Practices in Supporting MDS Patients Across All Stages of Their Journey
|
Feb 13, 2024 |
|
Marwan Fakih, MD - Expert Lines of Thought in Sequencing Later Lines of Therapy in Advanced CRC
|
Feb 01, 2024 |
|
Ana C. Garrido-Castro, MD / Sarah L. Sammons, MD - TROP2-Directed Antibody-Drug Conjugates for Breast Cancer: The Clinical Significance of the Construct
|
Jan 25, 2024 |
|
Elena Castro, MD, PhD - Radioligand Therapy and Therapeutic Sequencing in mCRPC
|
Jan 03, 2024 |
|
Edward B. Garon, MD, MS - Abundance of Choice at First Line, Lack of Options Beyond: Addressing Unmet Needs in NSCLC Without Actionable Mutations
|
Dec 28, 2023 |
|
Angela Lamarca, MD, PhD, MSc - Overcoming Barriers to Better Care in CCA: Keys to Optimising Multidisciplinary Care, Molecular Testing, and Targeted Treatment
|
Dec 19, 2023 |
|
Karim Fizazi, MD, PhD - Radioligand Therapy for Prostate Cancer: Predicting Who May Benefit and Who May Not
|
Dec 19, 2023 |
|
Ken Herrmann, MD, MBA - Evolving Evidence of Radioligand Therapy in Metastatic Prostate Cancer: A 2023 Clinical Round-Up From Key Congresses
|
Dec 11, 2023 |
|
Brian I. Rini, MD, FASCO - Doubling and Tripling Up: Maximizing Outcomes With Combination Therapies in Renal Cell Carcinoma
|
Dec 11, 2023 |
|
Aditya Bardia, MD, MPH - When HER2 Is Low or Negative: Emerging Evidence on Antibody-Drug Conjugates for Hormone Receptor-Positive and Triple-Negative Breast Cancers
|
Dec 01, 2023 |
|
Karim Fizazi, MD, PhD - The Science and the Art of Modern Prostate Cancer Care: Improving Patient Outcomes Through Intensification and Individualisation of Treatment
|
Nov 16, 2023 |
|
Lorenza Rimassa, MD - When One Size Doesn’t Fit All: Optimising Molecular Testing and Personalising Treatment Planning in Cholangiocarcinoma
|
Oct 24, 2023 |
|
Wong Seng Weng, MBBS, MRCP, FAMS - Treatment Approaches in EGFR-Mutant NSCLC Post-TKI and Chemotherapy: What Now and What Next?
|
Sep 29, 2023 |
|
David Planchard, MD, PhD - Catching Up on CEACAM5 in NSCLC: The Whys and Hows of Detection and Targeting
|
Sep 29, 2023 |
|
Gilles Salles, MD, PhD - Differentiating Decisions in Transplant-Ineligible Relapsed/Refractory DLBCL: What Are Our Options, and How Do We Choose Between Them?
|
Sep 26, 2023 |
|
Amit Singal, MD, MS - Recognising the Rationale and Understanding the Outcomes for CTLA-4 Targeted Therapies in Advanced HCC
|
Sep 19, 2023 |
|
David Malka, MD, PhD - Let’s Get Personal: Effective and Individualised Management of Targeted Therapies in Cholangiocarcinoma
|
Sep 14, 2023 |
|
Frank Siebenhaar, MD - Indolent Isn’t Insignificant: Raising Awareness of Systemic Mastocytosis and Its Symptoms
|
Sep 14, 2023 |
|
Arndt Vogel, MD - Modern Management of Cholangiocarcinoma: Sharing Evidence, Experience, and Expertise
|
Jul 31, 2023 |
|
Javier Cortés, MD, PhD - Updates on HER3-Targeted Therapies in NSCLC and Breast Cancer
|
Jul 24, 2023 |
|
Joe O'Sullivan, MD, PhD, FRCR - Evolving Evidence of Radioligand Therapy in Metastatic Prostate Cancer: A 2023 Clinical Round-Up From Key Congresses
|
Jul 18, 2023 |
|
Michael K. Wong, MD, PhD, FRCPC - Oncolytic Immunotherapies for Skin Cancer: Feasible and Practical Considerations
|
Jul 18, 2023 |
|
Johnny Mahlangu, MBBCH, MMed, FCPath - Redefining Balance in Hemophilia: Can We Restore Hemostasis by Inhibiting Anticoagulation?
|
Jul 17, 2023 |
|
D. Ross Camidge, MD, PhD - Mastering MET and cMET and Recognizing Their Role in Advanced NSCLC
|
Jun 27, 2023 |
|
Sara A. Hurvitz, MD, FACP - Clinical Case Challenge: Implementing ADCs Into Routine mTNBC Treatment Plans
|
Jun 27, 2023 |
|
Kevin Harrington, PhD, FRCR, FRCP - After More Than a Decade: Can We Now Enhance Treatment of Patients With LA SCCHN?
|
Jun 27, 2023 |
|
Aditya Bardia, MD, MPH - Keeping to Target in mTNBC: Optimising Outcomes With Antibody-Drug Conjugates in Practice
|
Jun 19, 2023 |
|
Sara A. Hurvitz, MD, FACP - Drug-Induced Interstitial Lung Disease and Breast Cancer: Knowing the Odds and Managing the Risk
|
Jun 19, 2023 |
|
Arndt Vogel, MD - Options and Opportunities in Cholangiocarcinoma: Novel Approaches for Targeting FGFR Alterations
|
Jun 19, 2023 |
|
Geoffrey Ku, MD - Here’s The Challenge! Overcoming Tumour Heterogeneity in Gastric/GEJ Cancers
|
Jun 13, 2023 |
|
Nick Pavlakis, MBBS, PLD / Kohei Shitara, MD - The Evolution of Treatment for Advanced Gastric and Oesophageal Cancers: New Insights From Key Congresses
|
May 18, 2023 |
|
Julia Rotow, MD / Javier Cortés, MD - HER3-Targeted Therapies: How Might These Benefit Our Patients?
|
May 12, 2023 |
|
Stefano Fanti, MD - Evolving Evidence of Radioligand Therapy in Metastatic Prostate Cancer: A 2023 Clinical Round-Up From Key Congresses
|
Apr 19, 2023 |
|
Emmanuella Guenova, MD, PhD - ‘T’ing Up Management of Mycosis Fungoides and Sézary Syndrome: Evaluating Blood Involvement and Its Impact on Patient Care
|
Apr 19, 2023 |
|
Kevin Harrington, PhD, FRCR, FRCP - When CPS is Between 1 and 19, How Would You Manage Recurrent/Metastatic SCCHN?
|
Apr 13, 2023 |
|
Jun-ichi Nishimura, MD, PhD / Austin Kulasekararaj, MD, FRCPath / Jeffrey Szer, MBBS, FRACP - Haemolysis in Paroxysmal Nocturnal Haemoglobinuria: Applying Assessment and Mitigation Strategies for Patients Receiving Complement Inhibitors
|
Apr 13, 2023 |
|
Thomas Powles, MBBS, MRCP, MD - Education, Collaboration and Communication: Aligning Patient and Clinical Priorities in Locally Advanced and Metastatic Urothelial Carcinoma
|
Apr 04, 2023 |
|
Alicia K. Morgans, MD, MPH - What Would You Do Next? Exploring Expert Perspectives on Clinical Cases and Compelling Questions in mHSPC and nmCRPC
|
Apr 04, 2023 |
|
Mary Frances McMullin, MD, FRCP, FRCPath - Managing Myelofibrosis: Can We Do More to Address Cytopenias, Reduce Transfusion Burden, and Improve Quality of Life?
|
Mar 29, 2023 |
|
Arndt Vogel, MD - Mobilising the Multidisciplinary Team: Collaborative Strategies to Improve Care in Early- to Intermediate-Stage HCC
|
Mar 28, 2023 |
|
Silke Gillessen, MD - Optimal Treatment of mCRPC: What Is the Place of Radioligand Therapy?
|
Mar 23, 2023 |
|
Gerald Prager, MD - Don't Leave a Drug on the Table: Maximising Use and Benefits of Later-Line Treatments for Advanced Colorectal Cancer
|
Mar 23, 2023 |
|
Solange Peters, MD, PhD - Advancing Our Patient-Centered Approach to Care in ALK-Positive Metastatic Non-Small Cell Lung Cancer
|
Mar 23, 2023 |
|
Tanios Bekaii-Saab, MD - Expert Perspectives on Treatment Sequencing in Advanced CRC: Keys to Reaching Later Lines of Therapy
|
Mar 23, 2023 |
|
Robert L. Coleman, MD - New Horizons in Cervical Cancer: Spotlight on Antibody-Drug Conjugates
|
Feb 08, 2023 |
|
Bruno Sangro, MD, PhD - A New Era in the Management of Advanced HCC: Sequencing Therapies for the Second-Line and Beyond
|
Jan 06, 2023 |
|
Frederique Penault-Llorca, MD, PhD - Setting Our Sights on Actionable Mutations in Cholangiocarcinoma: The Who, What, When, Why, and How of Testing
|
Jan 06, 2023 |
|
Susana Banerjee, MBBS, MA, PhD - When Patients With Advanced Endometrial Cancer Progress: Decisions in Treatment Initiation and Optimisation
|
Dec 28, 2022 |
|
Isabelle Ray-Coquard, MD, PhD - Turning Advanced Ovarian Cancer Into a Chronic Disease One Step at a Time
|
Dec 28, 2022 |
|
Egbert F. Smit, MD, PhD - Novel Antigenic Targets for Antibody-Drug Conjugates in NSCLC
|
Dec 14, 2022 |
|
Kjeld Schmiegelow, MD, DMSci - Asparaginase Therapy in Children and Young Adults With ALL/LBL: When You Need to Switch
|
Dec 05, 2022 |
|
Paolo Antonio Ascierto, MD - Emerging Data on Adjuvant Immunotherapy for Resected Melanoma: What Changes?
|
Nov 17, 2022 |
|
Mohamad Mohty, MD, PhD - Veno-Occlusive Disease: Who to Treat, How to Treat, When to Treat
|
Nov 01, 2022 |
|
Noemi Reguart, MD, PhD - Evaluating the Evidence for Emerging Therapies in NSCLC: Highlights From Summer/Fall 2022
|
Oct 27, 2022 |
|
Rana R. McKay, MD - Practice Series on Translating Data Into Practice in mCRPC: The Evolving Role of Radiopharmaceuticals
|
Oct 19, 2022 |
|
Contemporary Management of Prostate Cancer: Updated Approaches for Improved Outcomes in nmCRPC and mHSPC
|
Oct 04, 2022 |
|
Expert Guidance for Improving Outcomes in Advanced NSCLC: Utilising ADCs in Practice
|
Oct 03, 2022 |
|
Right Drug, Right Patient, Right Time: Cases in “Precisionalised” Treatment of Advanced NSCLC
|
Sep 29, 2022 |
|
Managing Cytopenic Myelofibrosis: New and Emerging Therapies and Who May Benefit
|
Sep 29, 2022 |
|
Hot Topics and Controversies in Adjuvant Therapy for Early-Stage, EGFR-Mutant NSCLC
|
Sep 20, 2022 |
|
Reassessing Management of Advanced and Recurrent Endometrial Cancer: The Value of Multidisciplinary and Overall Care
|
Sep 07, 2022 |
|
Personalised Management of Newly Diagnosed Secondary Acute Myeloid Leukaemia: Determining Factors That Impact Treatment Decisions
|
Sep 07, 2022 |
|
Question Time: Applying New Therapies for the Management of mTNBC
|
Aug 29, 2022 |
|
New Biomarkers, New Targets in Advanced NSCLC
|
Aug 17, 2022 |
|
Addressing the Triple Challenge of Myelofibrosis: Symptoms, Splenomegaly, and Cytopenias
|
Aug 01, 2022 |
|
IAP Antagonists in Oncology: What Do We Know?
|
Jul 25, 2022 |
|
Practical Guidance for Identifying and Managing Patients With Advanced MET Exon 14-Skipping NSCLC
|
Jul 11, 2022 |
|
Insights on the Increasing Impact of Emerging Therapies in NSCLC: Highlights From Spring 2022
|
Jun 30, 2022 |
|
Managing the Nuances of Paroxysmal Nocturnal Haemoglobinuria: Practical Strategies for Patients Receiving Complement Inhibitors
|
May 26, 2022 |
|
Managing Thrombosis in Cancer: A Double Debacle and Then Add COVID
|
May 18, 2022 |
|
‘B’ Vigilant: HCC Surveillance Protocols in Patients With Chronic Hepatitis B
|
May 16, 2022 |
|
Personalising Management of Advanced RCC: How I Treat
|
May 16, 2022 |
|
Immunotherapeutic Approaches in the Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia: Insights From the Real World
|
May 05, 2022 |
|
A Clinical Conversation on Metastatic Hormone-Sensitive Prostate Cancer: Intensifying Therapy Earlier in the Disease Course
|
Apr 26, 2022 |
|
Complex Cases of Comorbidities in Patients With HCV
|
Apr 21, 2022 |
|
"Defining the Diagnosis and Management of Pyruvate Kinase Deficiency"
|
Apr 20, 2022 |
|
Applying Revised Treatment Guidelines for Advanced Hepatocellular Carcinoma: Considerations in Real-Life Practice
|
Mar 01, 2022 |
|
The Place of Radiopharmaceuticals in an Evolving Treatment Landscape: Addressing Perceptions With Clinical Evidence to Optimise Outcomes in Men With Metastatic Prostate Cancer
|
Feb 28, 2022 |